Piramal Alternatives injects Rs 110 Cr in Biodeal Pharmaceuticals
India, April 9 -- Piramal Alternatives, the fund management division of the Piramal Group, has announced a significant investment of Rs 110 crore in Biodeal Pharmaceuticals, a New Delhi-based contract development and manufacturing company, facilitated through convertible instruments from its Performing Credit Fund.
The funding will be directed towards improving infrastructure and capacities, upgrading technology, and underlay a dedicated nutraceuticals manufacturing facility.
Biodeal is a key player in contract manufacturing, offering a wide range of products. It is among India's leading manufacturer of nasal sprays catering to marquee international and domestic pharmaceutical companies.
Kalpesh Kikani, CEO, Piramal Alternatives said, ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.